Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer

BACKGROUND: Clinical trials of HER2-directed therapy that omit neoadjuvant conventional chemotherapy for HER+ breast cancer demonstrate that a subset of patients still obtains a pCR. Identifying tumor characteristics which predict pCR may help select patients for de-escalated neoadjuvant dual HER2-t...

Descripción completa

Detalles Bibliográficos
Autores principales: Lander, Eric M, Rappazzo, Katherine C, Huang, Li-Ching, Hu, Jiun-Ruey, Chen, Heidi, Shyr, Yu, Abramson, Vandana G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Breast Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907044/
https://www.ncbi.nlm.nih.gov/pubmed/36495309
http://dx.doi.org/10.1093/oncolo/oyac247

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907044/
https://www.ncbi.nlm.nih.gov/pubmed/36495309
http://dx.doi.org/10.1093/oncolo/oyac247

Ejemplares similares